

Severity of disease and mortality for hospitalized patients with community-acquired viral pneumonia compared to patients with community-acquired bacterial pneumonia

Richard Y Kim^{1*}, Thomas R Chandler², Stephen P. Furmanek², Timothy L Wiemken³, Julio A Ramirez², and Rodrigo Cavallazzi¹

Abstract

Background: There exists a large body of literature to help identify, diagnose, treat, and manage community-acquired pneumonia (CAP). Despite this, there is little data that directly compares the clinical syndromes and complications of pure bacterial pneumonia to pure viral pneumonia. Our study compares the clinical presentation, morbidity and mortality of viral vs. bacterial etiologies of CAP.

Methods: This was a secondary data analysis of the Community-Acquired Pneumonia Organization (CAPO) international study database. Data was collected concerning patient demographics, physical examination findings, laboratory findings, radiological findings, severity of illness, and clinical outcomes and stratified according to the two study groups, CAVP and CABP. A microbiological diagnosis of CABP was based on the isolation of a bacterium from a respiratory sample, blood culture and/or identification of a urinary antigen for Streptococcus or Legionella; microbiological diagnosis of CAVP was based on polymerase chain reaction or antigen detection from respiratory samples.

Results: Our study included 1,913 patients. Of these, 286 (15.0%) had viral infection, while 1,627 (85.0%) had CAVP. We found that bacterial CAP patients are older, more frequently male, and suffer from a higher proportion of comorbidities when compared to viral CAP patients. Comparison of physical exam findings and laboratory values failed to find a clinically significant difference between bacterial and viral CAP patients. When comparing severity of illness, bacterial CAP patients had greater frequency of PSI \geq class IV; however, viral CAP patients more frequently needed ICU admission, ventilator support, vasopressor support, and had higher rate of in hospital mortality.

Conclusions: Our study confirms the extreme difficulty differentiating CABP from CAVP using demographics, physical exam, or x-ray findings. We found no major clinical or laboratory findings distinguishing CABP from CAVP. The increased severity of illness of CAVP compared to bacterial etiologies shows that PSI scores may not be an accurate indicator of severity of disease. More studies are needed to identify the best process of care for patients with CAP, including the potential benefits of routine respiratory viral panel testing and empiric antiviral therapy.

DOI: 10.18297/jri/vol3/iss1/3

Received Date: October 26, 2018

Accepted Date: December 18, 2018

<https://ir.library.louisville.edu/jri/vol3/iss1/>

Affiliations:

¹Division of Pulmonary, Critical Care and Sleep Disorders, University of Louisville

²Division of Infectious Diseases, University of Louisville

³Saint Louis University Center for Health Outcomes Research (SLUCOR)

This original article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in The University of Louisville Journal of Respiratory Infections by an authorized editor of ThinkIR. For more information, please contact thinkir@louisville.edu.

Recommended Citation:

Kim, Richard Y.; Chandler, Thomas; Furmanek, Stephen P.; Wiemken, Timothy Lee; and Cavallazzi, Rodrigo (2019) "Severity of disease and mortality for hospitalized patients with community-acquired viral pneumonia compared to patients with community-acquired bacterial pneumonia," *The University of Louisville Journal of Respiratory Infections*: Vol. 3 : Iss. 1, Article 3.

Introduction

Pneumonia is an extremely common, yet exceedingly dangerous condition that makes up 423,000 emergency room visits and is the 8th leading cause of death in the United States, according to the CDC [1]. Inpatient community-acquired pneumonia (CAP) treatment is often empiric and laboratory testing may not result in a definite organism [2]. It has been demonstrated that the microbial etiology of roughly 30%-60% of CAPs treated in the inpatient setting remains unidentified [3-6]. Of those admitted to the hospital, 10-20% of patients are admitted to the ICU [7]. While imaging and prognosticating tools like the CURB-65 and Pneumonia Severity Index assist in the diagnosis and severity assessment of pneumonia, distinguishing between viral and bacterial pneumonia remains a challenge [8].

Bacterial pneumonia is a major cause of pathogen identified CAP. For example, *Streptococcus pneumoniae* is the most common cause of bacterial pneumonia, causing significant morbidity and mortality [7]. Tools like procalcitonin levels are

helpful in the diagnosis and management of bacterial pneumonia [9]. On the other hand, viral pneumonia, a significant contributor to the prevalence of CAP, is identified by polymerase chain reaction (PCR) in more than 25% of cases using nasopharyngeal swabs and up to 40% when using lower respiratory tract samples [10]. Tools like rapid antigen testing and real time PCR assist in the diagnosis of several viral pneumonias [11]. Furthermore, morbidity and mortality of bacterial pneumonia after a preceding viral infection increases [12].

There is a large body of literature to help physicians identify, diagnose, treat, and manage CAP. Despite this, there is little data that directly compares the clinical syndromes and complications of bacterial pneumonia to viral pneumonia. Our study aims to compare the clinical presentation, morbidity and mortality of purely viral to purely bacterial etiologies of CAP.

*Correspondence To: Richard Y Kim, MD
Work Address: 401 E Chestnut Street, Suite 310
Louisville, KY, United States, 40202
Work Email: richard.kim@louisville.edu

Copyright: © 2019 The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 

Methods

Study Design

This was a secondary data analysis of the Community-Acquired Pneumonia Organization (CAPO) international study database. This multinational database is coordinated by the University of Louisville School of Medicine, Department of Medicine, Division of Infectious Diseases. Investigators from 130 hospitals across 30 countries perform data collection designed by the University of Louisville. Data is electronically transferred and validated by research associates at the University of Louisville [13].

Subjects

Patients were eligible for inclusion in analysis if they were hospitalized with CAP and a microbiological diagnosis of a viral or bacterial infection was established. Patients were enrolled from 2001 to 2017 and categorized into two groups: those with confirmed bacterial infection and those with confirmed viral infection. Patients without an identified bacterial or viral organism were excluded from the study. Additionally, patients with any coinfection were excluded.

Study Definitions

Community-acquired pneumonia (CAP):

A patient was defined as having CAP when the following 3 criteria were met: 1) presence of a new pulmonary infiltrate on chest radiograph and/or chest computed tomography scan at the time of hospitalization, defined by a board-certified radiologist's reading; 2) at least 1 of the following: a) new cough or increased cough or sputum production, b) fever $>37.8^{\circ}\text{C}$ (100.0°F) or hypothermia $<35.6^{\circ}\text{C}$ (96.0°F), c) changes in leukocyte count (leukocytosis: >11000 cells/ μL ; left shift: $>10\%$ band forms/ mL ; or leukopenia: <4000 cells/ μL); and 3) no alternative diagnosis at the time of hospital discharge that justified the presence of criteria 1 and 2 [14].

Hospitalization with community-acquired bacterial pneumonia (CABP) vs. community-acquired viral pneumonia (CAVP):

A microbiological diagnosis of CABP was based on the isolation of a bacterium from a respiratory sample, blood culture and/or identification of a urinary antigen for Streptococcus or Legionella; microbiological diagnosis of CAVP was based on polymerase chain reaction or antigen detection from respiratory samples.

Coinfection:

A patient was defined as having coinfection if more than one microorganism was identified. All patients with coinfections were excluded from analysis.

Table 1 Most common pathogens isolated in CAVP

Pathogen	n (%)
Influenza H1N1	250 (87)
Influenza H2N2	11 (4)
Rhinovirus	8 (3)
Respiratory Syncytial Viral (A,B)	5 (2)
Parainfluenza Virus (1,2,3)	5 (2)
Adenovirus	4 (1)
Respiratory Syncytial Virus B	1 (0)
Influenza B	1 (0)
Coronavirus NL63	1 (0)

Table 2 Most common pathogens isolated in CABP

Pathogen	n (%)
<i>Streptococcus pneumoniae</i>	858 (53)
<i>Haemophilus influenzae</i>	115 (7)
MSSA	99 (6)
<i>Legionella spp.</i>	95 (6)
MRSA	79 (5)
<i>Pseudomonas aeruginosa</i>	72 (4)
<i>Mycobacterium tuberculosis</i>	61 (4)
<i>Mycoplasma pneumoniae</i>	56 (3)
<i>Klebsiella pneumoniae</i>	50 (3)
<i>Escherichia coli</i>	35 (2)
<i>Moraxella catarrhalis</i>	34 (2)
<i>Chlamydia pneumoniae</i>	18 (1)
<i>Acinetobacter spp.</i>	10 (1)
<i>Nontuberculous mycobacteria</i>	8 (0)
<i>Proteus spp.</i>	8 (0)
<i>Enterobacter spp.</i>	7 (0)
<i>Streptococcus pyogenes</i>	6 (0)
<i>Pseudomonas pseudomallei</i>	4 (0)
Other	12 (1)

Measurements

Data was collected concerning patient demographics, physical examination findings, laboratory findings, radiological findings, severity of illness, and clinical outcomes and stratified according to the two study groups, CAVP and CABP.

Statistical Analysis

Descriptive statistics were performed, with frequencies with percentages as well as medians with interquartile ranges reported for categorical and continuous variables, respectively. Chi-squared tests and Mann-Whitney U-tests were performed to compare categorical and continuous variables. P-values of less than 0.05 were considered statistically significant. R v 3.4.3 was used for all analyses [15].

Results

Our study included 1913 patients. Of these, 286 (15.0%) had CAVP, while 1,627 (85.0%) had CABP. The most common organisms identified for patients CAVP and CABP depicted in **Tables 1 and 2**, respectively.

1. Patient Demographics

Patients with CABP were older (63 [IQR: 31] vs. 48 [IQR: 28] years; $P < 0.001$) and were more frequently male (64% vs 51%; $P < 0.001$) than patients with CAVP. A higher proportion of co-morbidities, including chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), Human Immunodeficiency Virus (HIV), stroke, and neoplastic diseases were also more commonly found in patients with CABP in comparison to those with CAVP.

2. Physical Examination Findings

Comparison between vitals measurements are shown in **Table 3**. While many variables were statistically significant, the differences between the CABP and CAVP groups were not considered clinically significant.

Table 3 Patient demographics, physical examination findings, laboratory findings, and radiological findings

Variable	CABP	CAVP	
Total study population, n	1627	286	
Demographics			P-value
Male sex, n (%)	1033 (64)	145 (51)	<0.001
Age, Median(IQR)*	63 (31)	48 (28)	<0.001
Chronic obstructive pulmonary disease	364 (22)	41 (14)	0.002
Diabetes mellitus	282 (17)	43 (15)	0.393
Current smoker	275 (17)	58 (20)	0.176
Congestive heart failure	227 (14)	27 (9)	0.038
HIV disease	200 (12)	8 (3)	<0.001
Stroke	162 (10)	8 (3)	<0.001
Neoplastic disease	160 (10)	12 (4)	0.002
Renal disease	156 (10)	21 (7)	0.268
Chronic renal failure	130 (8)	22 (8)	>0.999
Home oxygen	30 (4)	4 (1)	0.032
Physical Examination Findings		Median (IQR)	P-value
Systolic blood pressure (mmHg)	119 (33)	120 (34)	0.01
Heart rate (Beats/Minute)	104 (31)	100 (28)	0.026
Diastolic blood pressure (mmHg)	70 (20)	72.5 (23)	<0.001
Temperature (Degrees Celsius)	37.8 (1.9)	37.8 (1.7)	0.073
Respiratory rate (Breaths/Minute)	24 (8)	26 (12)	<0.001
Laboratory Findings		Median (IQR)	P-value
Serum sodium (mEq/L)	136 (7.0)	136 (6.0)	0.034
Serum glucose (mg/dl)	117 (50.0)	114 (44.0)	0.3
Hematocrit (percent)	38 (7.8)	39 (6.5)	<0.001
Blood urea nitrogen (mg/dL)	30 (32.0)	22 (21.5)	<0.001
Serum bicarbonate (mEq/L)	23.8 (6.2)	23 (6.0)	0.492
Serum procalcitonin (µg/L)	0.22 (0.94)	0.73 (4.39)	0.026
Radiological Findings		n (%)	P-value
Diffuse Bilateral, n (%)	20 (1)	9 (3)	0.03
Diffuse Unilateral, n (%)	11 (1)	15 (5)	<0.001
Multilobar Infiltrate, n (%)	857 (53)	166 (58)	0.095

3. Laboratory Findings

Comparison of laboratory values are shown in **Table 3**. Largest difference between the two groups was observed in the blood urea nitrogen (BUN), with bacterial pneumonia having a higher BUN value compared to that found in viral pneumonia (30 [IQR: 32] vs. 22 [IQR: 21.5] mg/dL; $P < 0.001$). Serum procalcitonin was only enumerated for 18 (6%) patients with CAVP and 118 (7%) patients with CABP; among those patients, serum procalcitonin was significantly higher for CABP compared to CAVP (0.73 [IQR: 4.39] vs. 0.22 [IQR: 0.94] µg/L; $p = 0.026$). Other differences were clinically or statistically non-significant.

4. Radiological Features

Radiological findings are shown in **Table 3**. On chest radiograph, patients with CAVP had more often diffuse bilateral infiltrate (3% vs 1%; $P = 0.03$) and unilateral diffuse infiltrate (5% vs 1%; $P < 0.001$). Multilobar infiltrates were also seen more commonly, though statistically non-significant, in CAVP than CABP (58% vs. 53%, $P = 0.095$).

5. Severity of Illness

Severity of disease on admission was characterized by frequency of pneumonia severity index (PSI) class IV or greater, need for ICU admission, altered mental status, need for ventilator support, and need for vasopressors, as shown in **Table 4**. There was a greater frequency of $PSI \geq$ class IV in CABP patients than

CAVP patients (38% vs. 30%; $P = 0.014$). Patients with CAVP more frequently needed intensive care admission (33% vs. 17%; $P < 0.001$), ventilator support (33% vs. 18%; $P < 0.001$), and vasopressors (20% vs. 9%; $P < 0.001$). Altered mental status was observed to have equal frequency in both groups (15%; $P = 0.928$).

6. Patient outcomes

Patient outcomes were characterized by time to clinical stability, hospital length of stay, in-hospital mortality, and 30-day mortality, as shown in **Table 4**. Times to clinical stability was not significantly different between CAVP and CABP groups (4 [IQR: 6] vs. 5 [IQR: 5] days); $P = 0.276$). Lengths of stay were 8 days in both groups. The percentage of in hospital mortality was significantly higher in patients suffering from CAVP compared to CABP (17% vs. 9%; $P < 0.001$); however, mortality at 30 days was not found to be significantly higher (24% vs. 21%; $P = 0.345$).

Discussion

Using the international CAPO database, we were able to retrospectively evaluate 1,913 patients admitted to the hospital for CAP to compare and contrast the clinical presentation, morbidity, and mortality of CAVP and CABP. Demographically, when compared to viral CAP, we found that bacterial etiologies are more commonly found in males and older patients. Bacterial pneumonia also is more frequent than viral pneumonia in patients with chronic obstructive pulmonary disease, congestive heart failure, human immunodeficiency virus, stroke, neoplastic disease, and those on home oxygen. Physical exam characteristics were found to be clinically non-significant between both groups. Furthermore, the blood urea nitrogen level, a nonspecific marker of plasma volume status, and frequency of PSI scores ≥ 4 were found to be higher in patients with CABP. However, the overlapping similarity in findings when comparing physical exam, laboratory data, and radiographic findings is in line with the extreme difficulty in diagnosing between bacterial vs. viral pneumonias. This is important to address as CAVP patients were observed to have a greater frequency of overall disease severity when comparing the frequency of need for ICU admission, ventilator support, vasopressor therapy, and mortality.

Table 4 Severity of illness and clinical outcomes

Total Study Population	Bacterial Infection	Viral Infection	
	1627	286	
Severity of Disease on Admission	Frequency (%)		P-value
Pneumonia severity index risk class IV or V	620 (38)	87 (30)	0.014
Need for intensive care	282 (17)	94 (33)	<0.001
Altered mental status	243 (15)	41 (15)	0.928
Need for ventilatory support	131 (18)	91 (33)	<0.001
Need for vasopressors	65 (9)	55 (20)	<0.001
Outcomes			P-value
Time to Clinical Stability, Median (IQR)	5 (5)	4 (6)	0.276
Length of Stay, Median (IQR)	8 (9)	8 (11)	0.195
In-Hospital Mortality, n (%)	148 (9)	50 (17)	<0.001
Mortality at 30 Days, n (%)	248 (21)	47 (24)	0.345

Our findings are both supported and refuted by currently established literature, reiterating the ambiguity between and difficulty in distinguishing the clinical presentation and severity of illness of bacterial vs. viral etiologies of CAP. For example, Johnstone found that viral pneumonias, in comparison to non-viral causes of pneumonia, were found to be more prevalent in older and frailer patients [16]. Other studies have identified a similar age difference between the two groups [6,17]. This is contrary to our finding that CABP patients are older than CAVP patients. Also, patients with COPD, CHF, and cerebrovascular disease were also found to be more commonly affected by viral CAP than bacterial CAP [17]. Similar to our findings, on the other hand, malignancy was observed to be more commonly found in patients with bacterial etiologies than viral [17]. HIV was also observed to be more common in bacterial CAP than viral CAP [18]. Despite these findings, it is important to also note that multiple studies found no significant difference in age or comorbidities between bacterial and viral etiologies of CAP [19-22].

Medical literature also supports our findings that physical exam and laboratory values are often unable to definitively distinguish between bacterial vs. viral pneumonias [17]. We did not find drastic differences between the two groups when comparing physical exam findings. These minor, yet significant differences were seen when comparing respiratory rate, blood pressure, and degree of tachycardia. We found higher BUN levels in patients suffering from CABP compared to CAVP. Higher levels of BUN have been shown to be associated with increased mortality in patients with CAP [23,24], however there were no studies found comparing BUN levels in CAVP vs. CABP. While we observed a significant difference in serum procalcitonin, the large proportion of patients missing those values should cause caution when interpreting these results. Though we observed significant, yet minor differences in serum glucose, hematocrit, and bicarbonate values between CABP and CAVP, Johnstone went on to state, "it seems unlikely that any constellation of symptoms, signs, and routine laboratory findings will ever reliably differentiate between the presence or absence of a virus.16 Furthermore, though there are several studies showing the clinical and laboratory findings of pure bacterial, pure viral, and combined bacterial-viral CAP infections [16,20,25], diagnosing and differentiating purely viral from bacterial CAP remains a problem as the etiology for a significant proportion of CAP remains unknown. It is estimated that 40-60% of CAP remains unidentified [3,26,27]. Caglayan states that bacterial CAP infections resemble combined bacterial-viral CAP in terms of mean age, immune status, leukocyte count, C-reactive protein (CRP) values, hospitalization duration and CURB-65 score [25].

We also evaluated disease severity in the setting of purely viral vs. purely bacterial CAP. CABP more frequently had PSI \geq class IV, however CAVP significantly showed higher frequencies of ICU admission, intubation, vasopressor support, and in hospital mortality. Though it has been previously demonstrated that PSI \geq class IV indicates increased disease severity and is strongly associated with ICU admission [28,29], our results show that PSI scores cannot be used to accurately prognosticate viral CAPs. Furthermore, literature suggests that PSI often underestimates the risk of patients with Influenza A H1N1 pneumonia [30,31] and neither PSI nor CURB-65 scores can be used to predict ICU admission or need for mechanical ventilation in influenza patients³¹. The CDC recommends early antiviral therapy for patients who are suspected of suffering from influenza [32]. There exist limitations to our study. First, this was a retrospective

study. Secondly, while the multicenter and international nature of the study increases the strength and generalizability of results, the data collection and other differences in process of care provide an unmeasurable confounding element that may have significant impact on data collection. Also, a large portion of patients included were afflicted by the H1N1 pandemic in 2009, that may explain the increased mortality for CAVP. Patients affected by H1N1 are observed to be younger in age and with fewer comorbidities [33]. Furthermore, pathogens identified from respiratory samples may represent colonization or active infection.

In conclusion, our study confirms the extreme difficulty differentiating CABP from CAVP using demographics, physical exam, or x-ray findings. We found no major clinical or laboratory findings distinguishing CABP from CAVP. The increased severity of illness of CAVP compared to bacterial etiologies shows that PSI scores may not be an accurate indicator of severity of disease. More studies are needed to identify the best process of care for patients with CAP, including the potential benefits of routine respiratory viral panel testing and empiric antiviral therapy.

Funding Source: Study was supported primarily by the Division of Infectious Diseases, University of Louisville, Kentucky

Conflict of Interest: All authors declared no conflict of interest in relation to the main objective of this work.

References

1. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final Data for 2014. *Natl Vital Stat Rep.* 2016 Jun;65(4):1-122. PMID:27378572
2. Kolditz M, Ewig S. Community-Acquired Pneumonia in Adults. *Dtsch Arztebl Int.* 2017 Dec;114(49):838-48. PMID:29271341
3. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al.; CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *N Engl J Med.* 2015 Jul;373(5):415-27. <https://doi.org/10.1056/NEJMoa1500245> PMID:26172429
4. Abers MS, Musher DM. Procalcitonin as a Marker of Etiology in Community-Acquired Pneumonia. *Clin Infect Dis.* 2018 May;66(10):1639. <https://doi.org/10.1093/cid/cix1089> PMID:29360957
5. Luchsinger V, Ruiz M, Zunino E, Martínez MA, Machado C, Piedra PA, et al. Community-acquired pneumonia in Chile: the clinical relevance in the detection of viruses and atypical bacteria. *Thorax.* 2013 Nov;68(11):1000-6. <https://doi.org/10.1136/thoraxjnl-2013-203551> PMID:23783373
6. Remington LT, Sligl WI. Community-acquired pneumonia. *Curr Opin Pulm Med.* 2014 May;20(3):215-24. <https://doi.org/10.1097/MCP.000000000000052> PMID:24614242
7. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. *Crit Care Clin.* 2013 Jul;29(3):563-601. <https://doi.org/10.1016/j.ccc.2013.03.009> PMID:23830654
8. Kolditz M, Braeken D, Ewig S, Rohde G. Severity Assessment and the Immediate and Long-Term Prognosis in Community-Acquired Pneumonia. *Semin Respir Crit Care Med.* 2016 Dec;37(6):886-96. <https://doi.org/10.1055/s-0036-1592127> PMID:27960212

9. Meisner M. Update on procalcitonin measurements. *Ann Lab Med.* 2014 Jul;34(4):263–73. <https://doi.org/10.3343/alm.2014.34.4.263> PMID:24982830
10. Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. *Eur Respir Rev.* 2016 Jun;25(140):178–88. <https://doi.org/10.1183/16000617.0076-2015> PMID:27246595
11. Falsey AR, Walsh EE. Viral pneumonia in older adults. *Clin Infect Dis.* 2006 Feb;42(4):518–24. <https://doi.org/10.1086/499955> PMID:16421796
12. Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. *Int J Infect Dis.* 2012 May;16(5):e321–31. <https://doi.org/10.1016/j.ijid.2012.01.003> PMID:22387143
13. CAPO. Community-Acquired Pneumonia Organization. 2018; www.caposite.com
14. Wiemken TL, Furmanek SP, Mattingly WA, Guinn BE, Cavallazzi R, Fernandez-Botran R, Wolf LA, English CL, Ramirez JA. Predicting 30-day mortality in hospitalized patients with community-acquired pneumonia using statistical and machine learning approaches. *Univ Louisville J Respir Infect.* 2017;1(3):10. <https://doi.org/10.18297/jri/vol1/iss3/10/>.
15. R: A language and environment for statistical computing. [computer program]. R Foundation for Statistical Computing; 2014.
16. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. *Chest.* 2008 Dec;134(6):1141–8. <https://doi.org/10.1378/chest.08-0888> PMID:18689592
17. Huijskens EG, Koopmans M, Palmen FM, van Erkel AJ, Mulder PG, Rossen JW. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. *J Med Microbiol.* 2014 Mar;63(Pt 3):441–52. <https://doi.org/10.1099/jmm.0.067108-0> PMID:24344207
18. Cilloniz C, Torres A, Polverino E, Gabarrus A, Amaro R, Moreno E, et al. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. *Eur Respir J.* 2014 Jun;43(6):1698–708. <https://doi.org/10.1183/09031936.00155813> PMID:24525448
19. Bello S, Mincholé E, Fandos S, Lasierra AB, Ruiz MA, Simon AL, et al. Inflammatory response in mixed viral-bacterial community-acquired pneumonia. *BMC Pulm Med.* 2014 Jul;14(1):123. <https://doi.org/10.1186/1471-2466-14-123> PMID:25073709
20. Voiriot G, Visseaux B, Cohen J, Nguyen LB, Neuville M, Morbieu C, et al. Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. *Crit Care.* 2016 Oct;20(1):375. <https://doi.org/10.1186/s13054-016-1517-9> PMID:27852281
21. Sangil A, Calbo E, Robles A, Benet S, Viladot ME, Pascual V, et al. Aetiology of community-acquired pneumonia among adults in an H1N1 pandemic year: the role of respiratory viruses. *Eur J Clin Microbiol Infect Dis.* 2012 Oct;31(10):2765–72. <https://doi.org/10.1007/s10096-012-1626-6> PMID:22549730
22. Kim JE, Kim UJ, Kim HK, Cho SK, An JH, Kang SJ, et al. Predictors of viral pneumonia in patients with community-acquired pneumonia. *PLoS One.* 2014 Dec;9(12):e114710. <https://doi.org/10.1371/journal.pone.0114710> PMID:25531901
23. Ma HM, Tang WH, Woo J. Predictors of in-hospital mortality of older patients admitted for community-acquired pneumonia. *Age Ageing.* 2011 Nov;40(6):736–41. <https://doi.org/10.1093/ageing/afro87> PMID:21771744
24. Janssens JP, Gauthey L, Herrmann F, Tkatch L, Michel JP. Community-acquired pneumonia in older patients. *J Am Geriatr Soc.* 1996 May;44(5):539–44. <https://doi.org/10.1111/j.1532-5415.1996.tb01439.x> PMID:8617902
25. Çağlayan Serin D, Pullukçu H, Çiçek C, Sipahi OR, Taşbakan S, Atalay S; Pneumonia Study Group. Bacterial and viral etiology in hospitalized community acquired pneumonia with molecular methods and clinical evaluation. *J Infect Dev Ctries.* 2014 Apr;8(4):510–8. <https://doi.org/10.3855/jidc.3560> PMID:2427518
26. Holter JC, Müller F, Bjørang O, Samdal HH, Marthinsen JB, Jenum PA, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. *BMC Infect Dis.* 2015 Feb;15(1):64. <https://doi.org/10.1186/s12879-015-0803-5> PMID:25887603
27. Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. *Intern Med.* 2013;52(3):317–24. <https://doi.org/10.2169/internalmedicine.52.8830> PMID:23370738
28. Vohra AS, Tak HJ, Shah MB, Meltzer DO, Ruhnke GW. Intensive Care Unit Admission With Community-Acquired Pneumonia. *Am J Med Sci.* 2015 Nov;350(5):380–6. <https://doi.org/10.1097/MAJ.0000000000000568> PMID:26445305
29. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. *Intensive Care Med.* 2011 Sep;37(9):1409–20. <https://doi.org/10.1007/s00134-011-2261-x> PMID:21660535
30. Estella A. Usefulness of CURB-65 and pneumonia severity index for influenza A H1N1v pneumonia. *Monaldi Arch Chest Dis.* 2012 Sep-Dec;77(3-4):118–21. PMID:23461247
31. Bjarnason A, Thorleifsdottir G, Löve A, Gudnason JF, Asgeirsson H, Hallgrímsson KL, et al. Severity of influenza A 2009 (H1N1) pneumonia is underestimated by routine prediction rules. Results from a prospective, population-based study. *PLoS One.* 2012;7(10):e46816. <https://doi.org/10.1371/journal.pone.0046816> PMID:23071646
32. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2011 Jan;60(1):1–24. PMID:21248682
33. Sohn CH, Ryoo SM, Yoon JY, Seo DW, Lim KS, Kim SH, et al. Comparison of clinical features and outcomes of hospitalized adult patients with novel influenza A (H1N1) pneumonia and other pneumonia. *Acad Emerg Med.* 2013 Jan;20(1):46–53. <https://doi.org/10.1111/acem.12062> PMID:23570478